Русская версия English version   
О журнале
Редакционная коллегия
Правила для авторов
Информация для читателей и авторов
Оглавление текущего номера
Архив
Контакты
Поиск

Отправить статью
 


Том 8   Выпуск 1   Год 2013
Андрианов А.М., Кашин И.А., Тузиков А.В.

Компьютерный поиск новых анти-ВИЧ-1 агентов - пептидомиметиков нейтрализующих антител - и оценка их потенциальной ингибиторной активности методами молекулярного моделирования

Математическая биология и биоинформатика. 2013;8(1):119-134.

doi: 10.17537/2013.8.119.

Список литературы

  1. Hartley O, Klasse PJ, Sattentau QJ, Moore JP. V3: HIV’s Switch-Hitter. AIDS Res Hum Retroviruses. 2005;21:171-189. doi: 10.1089/aid.2005.21.171
  2. Sirois S, Sing T, Chou KC. HIV-1 gp120 V3 loop for structure-based drug design. Curr. Protein Pept. Sci. 2005;6:413-422. doi: 10.2174/138920305774329359
  3. Sirois S, Touaibia M, Chou KC, Roy R. Glycosylation of HIV-1 gp120 V3 loop: towards the rational design of a synthetic carbohydrate vaccine. Curr. Med. Chem. 2007;14:3232-3242. doi: 10.2174/092986707782793826
  4. Andrianov AM. HIV-1 gp120 V3 loop for anti-AIDS drug discovery: computer-aided approaches to the problem solving. Expert Opin. Drug Discov. 2011;6:419-435. doi: 10.1517/17460441.2011.560603
  5. Kwong PD, Doyle ML, Casper DJ, Cicala C, Leavitt SA, Majeed S, Steenbeke TD, Venturi M, Chaiken I, Fung M, Katinger H, Parren PW, Robinson J, Van Ryk D, Wang L, Burton DR, Freire E, Wyatt R, Sodroski J, Hendrickson WA, Arthos J. HIV-1 evades antibody-mediated neutralization through conformational masking of receptor-binding sites. Nature. 2002;420:678-682. doi: 10.1038/nature01188
  6. Chen B, Vogan EM, Gong H, Skehel JJ, Wiley DC, Harrison SC. Structure of an unliganded simian immunodeficiency virus gp120 core. Nature. 2005;433:834-841. doi: 10.1038/nature03327
  7. Kwong PD, Wyatt R, Robinson J, Sweet RW, Sodroski J, Hendrickson WA. Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody. Nature. 1998;393:648-659. doi: 10.1038/31405
  8. Huang CC, Tang M, Zhang MY,Majeed S, Montabana E, Stanfield RL, Dimitrov DS, Korber B, Sodroski J, Wilson IA, Wyatt R, Kwong PD. Structure of a V3-containing HIV-1 gp120 core. Science. 2005;310:1025-1028. doi: 10.1126/science.1118398
  9. Trkola A,Dragic T, Arthos J, Binlay JM, Olson WC, Allaway GP, Cheng-Meyer C, Robinson J, Maddon PJ, Moore JP. CD4-dependent, antibody-sensitive interactions between HIV-1 and its co-receptor CCR-5. Nature. 1996;384:184-187. doi: 10.1038/384184a0
  10. Wu L, Gerard NP, Wyatt R, Choe H, Parolin C, Ruffing N, Borsetti A, Cardoso AA, Desjardin E, Newman W, Gerard C, Sodroski J. CD4-induced interaction of primary HIV-1 gp120 glycoproteins with the chemokine receptor CCR-5. Nature. 1996;384:179-183. doi: 10.1038/384179a0
  11. Dubay JW, Roberts SJ, Brody B, Hunter E. Mutations in the leucine zipper of the human immunodeficiency virus type 1 transmembrane glycoprotein affect fusion and infectivity. J. Virol. 1992;66:4748-4756.
  12. Wild C, Dubay JW, Greenwell T, Baird Jr T, Oas TG, McDanal C, Hunter E, Matthews T. Propensity for a leucine zipper-like domain of human immunodeficiency virus type 1 gp41 to form oligomers correlates with a role in virus-induced fusion rather than assembly of the glycoprotein complex. Proc. Natl. Acad. Sci. U.S.A. 1994;91:12676-12680. doi: 10.1073/pnas.91.26.12676
  13. Looney DJ, Fisher AG, Putney SD, Rusche JR, Redfield RR, Burke DS, Gallo RC, Wong-Staal F. Type-restricted neutralization of molecular clones of human immunodeficiency virus. Science. 1988;241:357-359. doi: 10.1126/science.3388046
  14. Meloen RH, Liskamp RM, Goudsmit J. Specificity and function of the individual amino acids of an important determinant of human immunodeficiency virus type 1 that induces neutralizing activity. J. Gen. Virol. 1989;70:1505-1512. doi: 10.1099/0022-1317-70-6-1505
  15. Hoxie JA. Toward an Antibody-Based HIV-1. Vaccine Annu. Rev. Med. 2010;61:135-152. doi: 10.1146/annurev.med.60.042507.164323
  16. Walker LM, Burton DR. Rational antibody-based HIV-1 vaccine design: current approaches and future directions. Curr. Opin. Immunol. 2010;22:358-366. doi: 10.1016/j.coi.2010.02.012
  17. Kwong PD, Mascola JR, Nabel GJ. Rational Design of Vaccines to Elicit Broadly Neutralizing Antibodies to HIV-1. Cold Spring Harb. Perspect. Med. 2011. doi: 10.1101/cshperspect.a007278. doi: 10.1101/cshperspect.a007278
  18. De Clercq E. New Approaches toward Anti-HIV Chemotherapy. J. Med. Chem. 2005;48:1297-1313. doi: 10.1021/jm040158k
  19. Este JA, Telenti A. HIV entry inhibitors. Lancet. 2007;370:81-88. doi: 10.1016/S0140-6736(07)61052-6
  20. Rusconi S, Scozzafava A, Mastrolorenzo A, Supuran CT. An update in the development of HIV entry inhibitors. Curr. Topics in Med. Chem. 2007;7:1273-1289. doi: 10.2174/156802607781212239
  21. Ryser HJ-P, Fluckiger R. Progress in targeting HIV-1 entry. Drug Discov. Today. 2005;10:1085-1094. doi: 10.1016/S1359-6446(05)03550-6
  22. Adamson CS, Freed EO. Novel approaches to inhibiting HIV-1 replication. Antiviral. Res. 2010;85:119-141. doi: 10.1016/j.antiviral.2009.09.009
  23. Tilton JC, Doms RW. Entry inhibitors in the treatment of HIV-1 infection. Antiviral Res. 2010;85:91-100. doi: 10.1016/j.antiviral.2009.07.022
  24. Orsega S. Treatment of adult HIV infection: antiretroviral update and overview. JNP. 2007;10:612-624. doi: 10.1016/j.nurpra.2007.08.022
  25. Turpin JA. The next generation of HIV/AIDS drugs: novel and developmental antiHIV drugs and targets. Expert Rev. Anti-infect. Ther. 2003;1:97-128. doi: 10.1586/14787210.1.1.97
  26. Vermeire K, Schols D, Bell TW. Inhibitors of HIV infection via the cellular CD4 receptor. Curr. Med. Chem. 2006;13:731-743. doi: 10.2174/092986706776055599
  27. Walker LM, Phogat SK, Chan-Hui PY, Wagner D, Phung P, Goss JL, Wrin T, Simek MD, Fling S, Mitcham JL, Lehrman JK, Priddy FH, Olsen OA, Frey SM, Hammond PW, Kaminsky S, Zamb T, Moyle M, Koff WC, Poignard P, Burton DR. Broad and potent neutralizing antibodies from an African donor reveal a new HIV-1 vaccine target. Science. 2009;326:285-289. doi: 10.1126/science.1178746
  28. Wu X, Zhou T, Zhu J, Zhang B, Georgiev I, Wang C, Chen X, Longo NS, Louder M, McKee K, O’Dell S, Perfetto S, Schmidt SD, Shi W, Wu L, Yang Y, Yang Z-Y, Yang Z, Zhang Z, Bonsignori M, Crump JA, Kapiga SH, Sam NE, Haynes BF, Simek M, Burton DR, Koff WC, Doria-Rose NA, Connors M, Mullikin JC, Nabel GJ, Roederer M, Shapiro L, Kwong PD, Mascola JR. Focused Evolution of HIV-1 Neutralizing Antibodies Revealed by Structures and Deep Sequencing. Science. 2011;333:1593-1602. doi: 10.1126/science.1207532
  29. Klein F, Gaebler C, Mouquet H, Sather DH, Lehmann C, Scheid JF, Kraft Z, Liu Y, Pietzsch J, Hurley A, Poignard P, Feizi T, Morris L, Walker BD, Fätkenheuer G, Seaman MS, Stamatatos L, Nussenzweig MC. Broad neutralization by a combination of antibodies recognizing the CD4 binding site and a new conformational epitope on the HIV-1 envelope protein. J. Exp. Med. 2012;209:1469-1479. doi: 10.1084/jem.20120423
  30. Hioe CE, Wrin T, Seaman MS, Yu X, Wood B, Self S, Williams C, Gorny MK, Zolla-Pazner S. Anti-V3 Monoclonal Antibodies Display Broad Neutralizing Activities against Multiple HIV-1 Subtypes. PLoS ONE. 2010;5(4): e10254. doi: 10.1371/journal.pone.0010254
  31. Jiang X, Burke V, Totrov M, Williams C, Cardozo T, Gorny MK, Zolla-Pazner S, Kong XP. Conserved structural elements in the V3 crown of HIV-1 gp120. Nat. Struct. Mol. Biol. 2010;17:955-961. doi: 10.1038/nsmb.1861
  32. Floris M, Masciocchi J, Fanton M, Moro S. Swimming Into Peptidomimetic Chemical Space Using pepMMsMIMIC. Nucl. Acids Res. 2011;39:261-269. doi: 10.1093/nar/gkr287
  33. Bernstein FC, Koetzle TF, Williams GJB, Meyer EF, Brice MD, Rodgers JR, Kennard O, Shimanouchi T, Tasumi M. The protein data bank. A computer-based archival file for macromolecular structures. J. Mol. Biol. 1977;112:535-542. doi: 10.1016/S0022-2836(77)80200-3
  34. Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The Protein Data Bank. Nucl. Acids Res. 2000;28:235-242. doi: 10.1093/nar/28.1.235
  35. Durranta JD, McCammon JA. BINANA: A novel algorithm for ligand-binding characterization. J. Mol. Graph. Model. 2011;29:888-893. doi: 10.1016/j.jmgm.2011.01.004
  36. Masciocchi J, Frau G, Fanton M, Sturlese M, Floris M, Pireddu L, Palla P, Cedrati F, Rodriguez-Tome P, Moro S. MMsINC: a large-scale chemoinformatics database. Nucl. Acids Res. 2009;37:D284-D290. doi: 10.1093/nar/gkn727
  37. Ballester PJ, Richards WG. Ultrafast shape recognition to search compound databases for similar molecular shapes. J. Comput. Chem. 2007;28:1711-1723. doi: 10.1002/jcc.20681
  38. Mason JS, Morize I, Menard PR, Cheney DL, Hulme C, Labaudiniere RF. New 4-point pharmacophore method for molecular similarity and diversity applications: overview of the method and applications, including a novel approach to the design of combinatorial libraries containing privileged substructures. J. Med. Chem. 1999;42:3251-3264. doi: 10.1021/jm9806998
  39. Karnachi P, Kulkarni A. Application of pharmacophore Engerprints to structure-based design and data mining. In: Pharmacophores and Pharmacophore Searches. Eds. Langer T, Hoffmannn RD. Germany, Weinheim: Wiley-VCH; 2006:193-206. doi: 10.1002/3527609164.ch9
  40. Trott O, Olson AJ. AutoDock Vina: improving the speed and accuracy of docking with a new scoring function, efficient optimization and multithreading. J. Comput. Chem. 2010;31:455-461.
  41. Kirkpatrick KS, Gelatt CD, Vecchi MP. Optimization by simulated annealing. Science. 1983;220:671-680. doi: 10.1126/science.220.4598.671
  42. Case DA, Darden TA, Cheatham TE, Simmerling CL, Wang J, Duke RE, Luo R, Crowley M, Walker RC, Zhang W, Merz KM, Wang B, Hayik S, Roitberg A, Seabra G, Kolossváry I, Wong KF, Paesani F, Vanicek J, Wu X, Brozell SR, Steinbrecher T, Gohlke H, Yang L, Tan C, Mongan J, Hornak V, Cui G, Mathews DH, Seetin MG, Sagui C, Babin V, Kollman PA. AMBER 11. San Francisco: University of California; 2010.
  43. Jorgensen WL, Chandrasekhar J, Madura JD, Impey RW, Klein ML. Comparison of simple potential functions for simulating liquid water. J. Chem. Phys. 1983;79:926-935. doi: 10.1063/1.445869
  44. Massova I, Kollman PA. Computational alanine scanning to probe protein-protein interactions: a novel approach to evaluate binding free energies. J. Am. Chem. Soc. 1999;121:8133-8143. doi: 10.1021/ja990935j
  45. Ablameiko SV, Abramov SM, Anishchenko VV, Medvedev SV, Paramonov NN, Chizh OP. Superkomp'iuternye konfiguratsii SKIF (SKIF supercomputer configuration). Minsk; 2005 (in Russ.).
  46. LaRosa GJ, Davide JP, Weinhold K, Waterbury JA, Profy AT, Lewis JA, Langlois AJ, Dressman GR, Boswell RN, Shadduk P, Holley LH, Karplus M, Bolognesi DP, Matthews TJ, Emini EA, Putney SD. Conserved sequence and structural elements in the HIV-1 principal neutralizing determinant. Science. 1990;249:932-935. doi: 10.1126/science.2392685
  47. Tian H, Lan C, Chen YH. Sequence variation and consensus sequence of V3 loop on HIV-1 gp120. Immunol. Lett. 2002;83:231-233. doi: 10.1016/S0165-2478(02)00101-3
  48. Basmaciogullari S, Babcock GJ, Van Ryk D, Wojtowicz W, Sodroski J. Identification of conserved and variable structures in the human immunodeficiency virus gp120 glycoprotein of importance for CXCR4 binding. J. Virol. 2002;76:10791-10800. doi: 10.1128/JVI.76.21.10791-10800.2002
  49. Cormier EG, Dragic T. The crown and stem of the V3 loop play distinct roles in human immunodeficiency virus type 1 envelope glycoprotein interactions with the CCR5 coreceptor. J. Virol. 2002;76:8953-8957. doi: 10.1128/JVI.76.17.8953-8957.2002
  50. Cormier EG, Tran DN, Yukhayeva L, Olson WC, Dragic T. Mapping the determinants of the CCR5 amino-terminal sulfopeptide interaction with soluble human immunodeficiency virus type 1 gp120-CD4 complexes. J. Virol. 2001;75:5541-5549. doi: 10.1128/JVI.75.12.5541-5549.2001
  51. Hoffman TL, LaBranche CC, Zhang W, Canziani G, Robinson J, Chaiken I, Hoxie JA, Doms RW. Stable exposure of the coreceptor-binding site in a CD4-independent HIV-1 envelope protein. Proc. Natl. Acad. Sci. U.S.A. 1999;96:6359-6364. doi: 10.1073/pnas.96.11.6359
  52. Huang CC, Lam SN, Acharya P, Tang M, Xiang SH, Hussan SS, Stanfield RL, Robinson J, Sodroski J, Wilson IA, Wyatt R, Bewley CA, Kwong PD. Structures of theCCR5Nterminus and of a tyrosine-sulfatedantibody with HIV-1 gp120 and CD4. Science. 2007;317:1930-1934. doi: 10.1126/science.1145373
  53. Hu Q, Trent JO, Tomaras GD, Wang Z, Murray JL, Conolly SM, Navenot JM, Barry AP, Greenberg ML, Peiper SC. Identification of Env determinants in V3 that influence the molecular anatomy of CCR5 utilization. J. Mol. Biol. 2000;302:359-375. doi: 10.1006/jmbi.2000.4076
  54. Shimizu N, Haraguchi Y, Takeuchi Y, Soda Y, Kanbe K, Hoshino H. Changes in and discrepancies between cell tropisms and coreceptor uses of human immunodeficiency virus type 1 induced by single point mutations at the V3 tip of the env protein. Virology. 1999;259:324-333. doi: 10.1006/viro.1999.9764
  55. Ivanoff LA, Looney DJ, McDanal C, Morris JF, Wong-Staal F, Langlois AJ, Petteway SRJr, Matthews TJ. Alteration of HIV-1 infectivity and neutralization by a single amino acid replacement in the V3 loop domain. AIDS Res. Hum. Retroviruses. 1991;7:595-603. doi: 10.1089/aid.1991.7.595
  56. Takeuchi Y, Akutsu M, Murayama K, Shimizu N, Hoshino H. Host range mutant of human immunodeficiency virus type 1: modification of cell tropism by a single point mutation at the neutralization epitope in the env gene. J. Virol. 1991;65:1710-1718.
  57. Ivanoff LA, Dubay JW, Morris JF, Roberts SJ, Gutshall L, Sternberg EJ, Hunter E, Matthews TJ, Petteway SRJr. V3 loop region of the HIV-1 gp120 envelope protein is essential for virus infectivity. Virology. 1992;187:423-432. doi: 10.1016/0042-6822(92)90444-T
  58. Grimaila RJ, Fuller BA, Rennert PD, Nelson MB, Hammarskjöld ML, Potts B, Murray M, Putney SD, Gray G. Mutations in the principal neutralization determinant of human immunodeficiency virus type 1 affect syncytium formation, virus infectivity, growth kinetics, and neutralization. J. Virol. 1992;66:1875-1883.
  59. Andrianov AM, Anishchenko IV, Tuzikov AV. Discovery of Novel Promising Targets for Anti-AIDS Drug Developments by Computer Modeling: Application to the HIV-1 gp120 V3 Loop. J. Chem. Inf. Model. 2011;51:2760-2767. doi: 10.1021/ci200255t
  60. Andrianov AM, Kornoushenko YuV Anishchenko IV, Eremin VF, Tuzikov AV. Structural analysis of the envelope gp120 V3 loop for some HIV-1 variants circulating in the countries of Eastern Europe. J. Biomol. Struct. Dynam. 2012:1-19. doi:10.1080/07391102.2012.706455. doi: 10.1080/07391102.2012.706455
Содержание
Оригинальная статья
Мат. биол. и биоинф.
2013;8(1):119-134
doi: 10.17537/2013.8.119
опубликована на рус. яз.

Аннотация (рус.)
Аннотация (англ.)
Полный текст (рус., pdf)
Список литературы

 
  Copyright ИМПБ РАН © 2005-2024